Compare DLHC & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLHC | BTMD |
|---|---|---|
| Founded | 1969 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.9M | 80.4M |
| IPO Year | N/A | N/A |
| Metric | DLHC | BTMD |
|---|---|---|
| Price | $5.63 | $2.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 25.7K | ★ 124.9K |
| Earning Date | 02-04-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 270.48 |
| EPS | 0.09 | ★ 0.78 |
| Revenue | ★ $344,497,000.00 | $195,645,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.80 |
| P/E Ratio | $62.78 | ★ $3.34 |
| Revenue Growth | N/A | ★ 1.34 |
| 52 Week Low | $2.72 | $2.32 |
| 52 Week High | $8.45 | $6.36 |
| Indicator | DLHC | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 44.38 |
| Support Level | $5.51 | $2.56 |
| Resistance Level | $5.65 | $2.80 |
| Average True Range (ATR) | 0.15 | 0.13 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 21.96 | 5.17 |
DLH Holdings Corp delivers health and readiness solutions for federal government customers through digital transformation and cyber security, science research and development, and systems engineering and integration. It provides technology-enabled business process, program management, and digital transformation solutions to U.S. government agencies, focusing on large-scale, technology-powered health and defense initiatives for agencies including HHS, VA, DoD, and their sub-agencies. Its revenues come from technology-enabled business process outsourcing, program management solutions, and public health research and analytics under time-and-materials, cost-reimbursable, and firm-fixed-price contracts.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.